Resources to help you manage out-of-pocket expenses for LENVIMA®, including information about the Eisai Assistance Program and the LENVIMA® Patient Assistance Program.
The LENVIMA® $0 Co-pay Program offers commercially insured patients a $0 co-pay for each prescription, with a $40,000 annual limit. Enrollment is required for those receiving LENVIMA® from a source other than Accredo or Biologics. Please call the Eisai Assistance Program at 1-866-61-EISAI (1-866-613-4724) for more information.
If you are deemed ineligible, there may be alternate funding options available.
Alternate funding assistance may also be available for those who are not eligible for the LENVIMA®.
*Maximum benefit: The LENVIMA® $0 Co-pay Program provides up to $40,000 per year to assist with the out-of-pocket costs for LENVIMA®. Depending on the insurance plan, your patient could have additional financial responsibility for any amounts over Eisai’s maximum liability.Eligibility criteria: Good toward the purchase of LENVIMA®
prescriptions. No substitutions permitted. Not available to patients eligible for state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE. Offer only available to patients with private, commercial insurance. Offer available to MA residents through June 30, 2019. May not be combined with any other coupon, discount, prescription savings card, free trial, or other offer. Void outside the USA and where prohibited by law. Eisai Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. Patients, physicians and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the program and complying with any other conditions imposed by insurance carriers on third-party payors. The value of this program is not contingent on any prior or future purchases. This program is solely intended to provide savings on a purchase of LENVIMA®. Use of this program for any one purchase does not obligate the patient to make future purchases of LENVIMA® or any other product. This offer will expire March 31, 2020.
The Eisai Assistance Program offers a number of services to provide information about access and reimbursement support, including
prior authorization information
alternate coverage/funding information
Patient Assistance Program (PAP) enrollment
expediting product access and minimizing barriers to access
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.
LENVIMA® (lenvatinib) is a prescription medicine that is used to treat certain kinds of cancer.
It is not known if LENVIMA is safe and effective in children.
The most common side effects of LENVIMA in people treated for thyroid cancer include tiredness; joint and muscle pain; decreased appetite; weight loss; nausea; mouth sores; headache; vomiting; rash, redness, itching, or peeling of the skin on your hands and feet; stomach (abdomen) pain; and hoarseness.
The most common side effects of LENVIMA in people treated for kidney cancer include tiredness; joint and muscle pain; decreased appetite; vomiting; nausea; mouth sores; swelling in your arms and legs; cough; stomach (abdomen) pain; trouble breathing; rash; weight loss; and bleeding
LENVIMA may cause fertility problems in males and females. Talk to your health care provider if this is a concern for you.
These are not all the possible side effects of LENVIMA. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit http://www.FDA.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information.
The information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care professional. All decisions regarding patient care must be made with a health care professional, considering the unique characteristics of the patient.
This site is intended for residents of the United States only. Any products discussed herein may have different product labeling in different countries.